|Systematic (IUPAC) name|
|Mol. mass||297.25916 g/mol|
|(what is this?)|
Isofagomine tartrate (planned trade name Plicera) is an experimental drug for the treatment of certain forms of Gaucher's disease, developed by Amicus Therapeutics and Shire plc. It has been granted orphan drug status by the European Medicines Agency (EMA). Isofagomine was invented by Mikael Bols and Troels Skrydstrup, and was first prepared by Jespersen and Bols.
Mechanism of action
β-glucocerebrosidase, an enzyme needed for the metabolisation of glucocerebroside, is misfolded in individuals with Gaucher's disease due to various mutations, one of which is called N370S. Isofagomine binds selectively to N370S glucocerebrosidase and restores its correct conformation and, consequently, enhances its activity about threefold.
- Imiglucerase, a recombinant human β-glucocerebrosidase for enzyme replacement therapy of Gaucher's disease
- Miglustat, another orphan drug for the treatment of Gaucher's disease with a different mechanism of action
- H. Spreitzer (20 June 2009). "Neue Wirkstoffe - Isofagomin tartrat". Österreichische Apothekerzeitung (in German) (13/2009): 736.
- Public summary of positive opinion for orphan designation of isofagomine tartrate for the treatment of Gaucher disease
- Jespersen, T. M.; Dong, W; Skrydstrup, T; Sierks, M.R; Lundt, I; Bols, M. (1994). "Isofagomine, a Potent New Glycosidase Inhibitor". Angew. Chem. Int. Ed. Engl. 33 (17): 1778–1779. doi:10.1002/anie.199417781.
- Dulsat, C., Mealy, N. (2009). "Isofagomine tartrate". Drugs of the Future 34 (1): 23. doi:10.1358/dof.2009.034.01.1323946.
- Richard A. Steet, Stephen Chung, Brandon Wustman, Allan Powe, Hung Do, and Stuart A. Kornfeld (2006). "The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanisms". PNAS 103 (37): 13813–8. doi:10.1073/pnas.0605928103. PMC 1564243. PMID 16945909.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|